Introduction {#sec1}
============

Obesity is a global health problem that is associated with numerous morbidities, including cardiovascular disease. Alarmingly, obesity has increased 28% in adults and 47% in children over the last 30 years \[[@B1]\]. The cardiovascular system responds to body fat accumulation, through a myriad of adaptations that include cardiac tissue remodeling \[[@B2]\]. Remodeling of the myocardium is characterized by increases in ventricular wall thickness and fibrosis, which culminate in the development of diastolic and systolic dysfunction and ultimately heart failure \[[@B2]\].

Molecular mechanisms underlying cardiac remodeling includes re-expression of genes normally active during development; this requires 'unpacking' of silenced genes via epigenetic mechanisms \[[@B3],[@B4]\] that entails post-translational modifications (PTMs) of DNA or histone proteins. As such, reports have implicated histone acetylation as a key regulator of cardiac remodeling and function \[[@B5],[@B6]\]. While lysine acetylation has traditionally been studied in the context of nucleosomal histones, recent proteomic reports have demonstrated that approximately 4500 proteins can be acetylated on approximately 15000 acetylation sites (e.g. lysine residues), suggesting a more complex role for the acetylome in biological functions \[[@B7]\]. While non-histone protein acetylation remains poorly understood, recent findings in cardiac biology suggest that non-histone acetylation can impact contractile function, energy metabolism, and cardiac remodeling \[[@B8]\]. For instance, acetylation of the sarcomeric protein myosin heavy chain was recently reported to increase contractile function in response to stress, whereas deacetylation by histone deacetylase (HDAC) 3 (HDAC3) decreased contractile performance \[[@B8]\].

Contractile performance of the working mammalian heart requires high demand for energy; more than half of these energy needs are met via fatty acid β oxidation followed by glucose oxidation \[[@B11],[@B12]\]. Mitochondria increasingly rely on fatty acid β oxidation in response to obesity for energy utilization with conservation of glucose metabolism \[[@B11],[@B12]\]. Chronically elevated circulating free fatty acids in obesity contribute to increased fatty acid uptake and β oxidation, providing an abundance of acetyl-CoA molecules for protein lysine acetylation \[[@B13],[@B14]\].

Based on reports above, we would postulate marked changes in cardiac protein acetylation associated with obesity. While the cardiac acetylome is an emerging topic of interest \[[@B15]\], our understanding of how obesity regulates cardiac lysine protein acetylation remains inadequate. In this report, we utilized MS/MS to examine the cardiac acetylome in a rodent model of obesity-induced cardiac remodeling. For this report, we relied on tandem mass-tagged (TMT) examination of the proteome and used proteome discoverer software to determine changes in peptide acetylation. Unlike standard enrichment methods that allow for the detection of low abundant peptide modifications, this method afforded us the opportunity to assess peptide acetylation and normalize our findings to total protein expression in one analysis. Through TMT-tagged MS, we identified approximately 2500 proteins in the myocardium, of which 65 were significantly regulated by obesity. In addition, we reported that 189 proteins were acetylated under conditions of diet-induced obesity (DIO), in which 14 proteins were significantly impacted by obesity. Moreover, Ingenuity Pathway Analysis (IPA) identified the Cardiovascular Disease Pathway as significantly impacted by DIO, as 47 of the 189 acetylated proteins identified encompassed this pathway. Of note, acetylated proteins were mostly found to be involved in energy metabolism and muscle contractility, in which acetylation was primarily increased for mitochondrial proteins and decreased for sarcomeric proteins. These findings highlight the potential impact for the cardiac acetylome in the regulation of cardiac pathophysiology.

Experimental {#sec2}
============

Experimental animals {#sec2-1}
--------------------

C57BL/6J mice were rendered obese by diet. Diet-induced obese C57BL/6J mice were given *ad libitum* access to a high-fat diet (HFD) consisting of 60% of total kilocalories from fat (Research Diets Inc. D12492) starting at 16 weeks of age, while lean controls were given *ad libitum* access to a low-fat diet (LFD) (control diet (CD)) consisting of 10% of total kilocalories from fat (Research Diet Inc. D12450B). Protein was similar for both diets (10% of total kilocalories). Caloric balance was provided by differences in carbohydrate amount. Mice were fed both diets for a total of 16 weeks. At the end of the protocol, hearts were collected and left ventricles (LVs) dissected for histology and biochemistry. Animal care and use were in compliance with the Institute of Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Use and Care Committee at the University of Nevada Reno. All experiments were in accordance with the National Institutes of Health (NIH) guidelines.

Real-time qRT-PCR {#sec2-2}
-----------------

RNA was isolated from the LVs of CD and HFD male mice using Qiazol (Qiagen) as per manufacturer's protocol. RNA was quantitated via Nanodrop ND-1000 spectrophotometer. cDNA was reverse transcribed from 500 ng of RNA via Verso cDNA Synthesis Kit (Thermo Scientific; AB-1453). Quantitative PCR (qPCR) amplification was performed on a Bio-Rad CF96X qPCR instrument (Bio-Rad). Mouse primers for qPCR were: atrial natriuretic peptide (ANP) (forward: 5′-GCC GGT AGA AGA TGA GGT CAT-3′, reverse: 5′-GCT TCC TCA GTC TGC TCA CTC -3′), brain natriuretic peptide (BNP) (forward: 5′-CGC TGG GAG GTC ACT CCT AT -3′, reverse: 5′-GCT CTG GAG ACT GGC TAG GAC TT -3′), Collagen 1 (forward: 5′-TTC TAG TTC CTG GGC CTA TCT-3′, reverse: 5′-GAT GCA GGA CAG ACC AAG AG-3′), and connective tissue growth factor 1 (Ctgf-1) (forward: 5′-ACC TGT GCC TGC CAT TAC -3′, reverse: 5′-GTC CCT TAC TTC CTG GCT TTA C-3′) and gene expression was examined and referenced to 18S (forward: 5′-GCC GCT AGA GGT GAA ATT CTT A-3′, reverse: 5′-CTT TCG CTC TGG TCC GTC TT-3′) gene expression. Amplicon abundance was calculated using the 2^−ΔΔ*C*^~T~ method. GraphPad Prism software was used for graph visuals, and included mean ± S.E.M. Statistical analysis was completed by ANOVA followed by post-hoc testing (Tukey's test was used for post-hoc analysis unless otherwise noted) using GraphPad Prism software. Statistical significance (defined as *P*\<0.05) was reported as applicable.

Histology {#sec2-3}
---------

LV tissue was fixed in 4% paraformaldehyde and processed using Leica ASP300S and paraffin embedded using Leica EG1160. PicroSirius Red staining was performed on LV tissue cross-sectioned at 5 μm as previously described \[[@B16]\]. Quantitation of collagen present in LV tissue was performed using ImageJ software and sections were imaged using Leica DMI3000B.

Immunoblotting {#sec2-4}
--------------

LV tissue was homogenized in ice-cold lysis buffer containing PBS (pH 7.4), 0.5% Triton X-100, 300 mM NaCl, and protease/phosphatase inhibitor cocktail (Thermo Fisher) using the Next Advance Bullet Blender. Lysates were clarified at 16000×***g*** for 5 min prior to protein concentration determination via BCA Protein Assay Kit (Pierce). Proteins were resolved by SDS/PAGE, transferred to nitrocellulose membranes (Bio-Rad), and membranes were blocked with 4% milk. Membranes were probed overnight with indicated primary antibodies for mouse monoclonal acetyl-lysine (Cell Signaling Technology; 9681), rabbit polyclonal acetyl-lysine (Cell Signaling Technology; 9441), acetyl-α-tubulin (Santa Cruz Biotechnology; sc-23950), α-tubulin (Santa Cruz Biotechnology; sc-23948), or total histone H3 (Cell Signaling Technology; 4499). Horseradish peroxidase (HRP)--conjugated secondary antibodies (Southern Biotech) were used at a concentration of 1:2000. SuperSignal West Pico chemiluminescence system (Thermo Scientific) and a ChemiDoc XRS+ imager (Bio-Rad) were used to detect protein expression.

LC and MS analysis {#sec2-5}
------------------

For these studies, biological replicates for control diet (CD; *n*=4) and HFD (*n*=5) were examined. Protein isolation and enzymatic digestion -- protein from LV tissue was homogenized, clarified, and quantitated, as described above in immunoblotting. Protein lysate was subsequently digested and desalted according to Lundby et al. \[[@B17]\] (*n*=5). Protein concentrations were then determined using BCA assay (Thermo Fisher Scientific, San Jose, CA). Proteins were then reduced and alkylated and subjected to methanol-chloroform precipitation prior to digestion with endoproteinase Lys-C (Wako, Richmond, VA). Followed by digestion with trypsin (Promega, Madison, WI) and desalting and concentration using C~18~ Sep-Pak Cartridges (Waters).

TMT isobaric labeling -- thirty micrograms of peptides from each sample were mass tagged using Thermo Fisher's TMT 10-plex isobaric label kit (catalog \# 90061) following the included protocol and pooled for analysis; samples were normalized to sample 8, which had the lowest abundance on the peptide assay. Basic reversed-phase fractionation -- pooled TMT-labeled peptides were fractionated by basic pH reversed-phase (BPRP) fractionation on an Ultimate 3000 HPLC (Thermo Scientific) using an integrated fraction collector. Elution was performed using a 10-min gradient of 0--20% solvent B followed by a 50-min gradient of solvent B from 20 to 45% (Solvent A 5.0% Acetonitrile, 10 mM ammonium bicarbonate pH 8.0, Solvent B 90.0% Acetonitrile, 10 mM ammonium bicarbonate pH 8.0) on a Zorbax 300Extend-C18 column (Agilent) at a flow rate of 0.4 ml/min. A total of 24 fractions were collected at 37-s intervals in a looping fashion for 60 min then combined to produce a total of 12 fractions. Peptide elution was monitored at a wavelength of 220 nm using a Dionex Ultimate 3000 variable wavelength detector (Thermo Scientific). Each fraction was then centrifuged to near dryness and desalted using C~18~ Sep-Pak Cartridges followed again by centrifugation to near dryness and reconstitution with 20 μl of 5% acetonitrile and 0.1% formic acid.

LC and MS -- BPRP fractions were then separated using an UltiMate 3000 RSLCnano system (Thermo Scientific, San Jose, CA) on a self-packed UChrom C18 column (100 μm × 35 cm). Separation was performed using a 180-min gradient of solvent B from 2 to 27% (Solvent A 0.1% formic acid, Solvent B Acetonitrile, 0.1% formic acid) at 50°C using a digital Pico View nanospray source (New Objectives, Woburn, MA) that was modified with a custom-built column heater and an ABIRD background suppressor (ESI Source Solutions, Woburn, MA). Briefly, the self-packed column tapered tip was pulled with a laser micropipette puller P-2000 (Sutter Instrument Co, Novato, CA) to an approximate id of 10 μm. The column was then packed with 1--2 cm of 5 μm Sepax GP-C18 (120A) (Sepax Technologies, Newark, DE) followed by 40 cm of 1.8 μm Sepax GP-C18 (120 A) at 9000 psi using a nano LC column packing kit (nanoLCMS, Gold River, CA).

Mass spectral analysis was performed using an Orbitrap Fusion mass spectrometer (Thermo Scientific, San Jose, CA). TMT analysis was performed using an MS3 multi-notch approach \[[@B18]\]. The MS1 precursor selection range is from 400 to 1400 m/z at a resolution of 120 K and an automatic gain control (AGC) target of 2.0 × 10^5^ with a maximum injection time of 100 ms. Quadrupole isolation at 0.7 Th for MS^2^ analysis using CID fragmentation in the linear ion trap with a collision energy of 35%. The AGC was set to 4.0 × 10^3^ with a maximum injection time of 150 ms. The instrument was operated in a top speed data-dependent mode with a most intense precursor priority with dynamic exclusion set to an exclusion duration of 60 s with a 10 ppm tolerance. MS2 fragment ions were captured in the MS3 precursor population. These MS3 precursors were then isolated within a 2.5 Da window and subjected to high energy collision-induced dissociation (HCD) with a collision energy of 55%. The ions were then detected in the Orbitrap at a resolution of 60000 with an AGC of 5.0 × 10^4^ and a maximum injection time of 150 ms. The data were then analyzed using Sequest (Thermo Fisher Scientific, San Jose, CA, version v.27, rev. 11.) and Proteome Discoverer (Thermo Scientific, San Jose, CA, version 2.1).

Peptide statistical analyses {#sec2-6}
----------------------------

Proteome Discoverer software was used to determine total protein and acetyl protein content within our samples. Search parameters were set for FASTA: Uniprot-*Mus musculus* (downloaded 7-17-2015) that contained 24088 sequences. The Proteome Discoverer peptide-level abundance data file was first transformed into a flat text file so that abundance data from each protein and its associated peptides were easily accessible for manipulation and analysis in the **R** programming language. More specifically, data from Proteome Discoverer was imported into Microsoft Access and SQL scripts were written to transform the data into a simple flat file so that each protein became a header for the subgroup of its associated peptides, and this row was clearly identified by its protein accession. Each peptide was represented by its (not necessarily unique) sequence, and two columns were included in the custom text file to clearly indicate whether the peptide was acetylated, and whether the Proteome Discoverer software used the peptide to account for the protein's total abundance. For example, redundant peptides were not used to account for the protein's total abundance. Additional information pertaining to methodology are highlighted in results.

IPA {#sec2-7}
---

Proteins identified as being acetylated were analyzed using IPA software (Qiagen, Redwood City, CA) following methodology previously described \[[@B19]\]. IPA is a well-cited standalone pathway analysis tool that is commonly used to examine total protein expression; we considered this in our evaluation of protein acetylation. IPA was used for our 65 total proteins that changed with obesity and also for our 189 acetylated proteins. For both the total proteome and acetylated proteins, each protein symbol was mapped to its corresponding gene and set within the context of its associated partners based on the Ingenuity Pathways Knowledge Base (IPKD). Networks of these genes were algorithmically generated based on their connectivity and assigned a score. The score takes into account the number of focus genes in the network and the size of the network to approximate how relevant this network is to the original list of focus genes. Canonical pathways analysis identified the pathways, from the IPA library of canonical pathways, which were most significant to the input dataset. For acetylated peptides, post-hoc input was used to show proteins in which acetylation increased or decreased in response to DIO. Protein--protein interactions were based on total protein analysis.

Data availability {#sec2-8}
-----------------

Data will be made freely available upon request. The MS proteomics data in the present paper have been deposited in the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository \[[@B20]\]: dataset identifier PXD008385.

Results {#sec3}
=======

Obesity-mediated cardiac remodeling {#sec3-1}
-----------------------------------

The cardiovascular system adapts to stressors such as obesity, in part, through structural remodeling of the myocardium that is characterized by cardiac hypertrophy and fibrosis, as well as metabolic plasticity, which typically results in cardiac dysfunction and heart failure \[[@B2]\]. Thus, this study used a mouse model of obesity-mediated cardiac remodeling, as a pathophysiological relevant model of human dietary behavior. Sixteen weeks' post-diet intervention, animals were killed, hearts were dissected and gross weights of heart weight and LV weight was assessed and normalized to tibia length. It should be noted that HFD animals were obese, hyperglycemic, and insulin resistant (data not shown) compared with their CD counterparts. Sixteen weeks of HFD led to a robust and significant increase in heart weight and LV weight ([Figure 1](#F1){ref-type="fig"}A), demonstrating obesity-mediated increase in cardiac hypertrophy. Real-time qPCR of ANP and BNP, fetal genes that increase with cardiac enlargement and used as clinical indicators of heart failure, were additionally assessed in the LV. Similar to increased heart enlargement, animals in the HFD group had a significant induction of ANP and BNP gene expression ([Figure 1](#F1){ref-type="fig"}B). Myocardial stress also typically results in cardiac fibrosis. Indeed, histological analysis of collagen stained LVs demonstrated a significant increase in cardiac fibrosis as assessed by PicroSirius Red staining ([Figure 1](#F1){ref-type="fig"}C) and quantitated ([Figure 1](#F1){ref-type="fig"}D) in animals under HFD conditions. These data were further supported, by gene expression analysis of collagen type 1 (Col1) and connective tissue growth factor 1 (Ctgf-1), genes that regulate extracellular matrix (ECM) production in the heart and are associated with fibrotic pathology \[[@B21]\]. Animals on the obesogenic diet (i.e. HFD) had a significant increase in *Col1* and *Ctgf-1* gene expression in the LV ([Figure 1](#F1){ref-type="fig"}E). Together, these data demonstrate a robust and sufficient model for obesity-mediated cardiac remodeling in response to HFD.

![Obesity-mediated cardiac hypertrophy and fibrosis\
Hearts were extracted from male C57BL6/J mice on CD or HFD and (**A**) heart weight and LV weight measured and normalized to tibia length. (**B**) RNA was isolated from LV tissue and *ANP, BNP* mRNA expression was analyzed via qPCR from animals on CD and HFD. (**C**) PicroSirius Red staining of collagen in LV tissue of CD and HFD animals. (**D**) Quantitation of collagen, fibrosis, present in LV tissue of CD and HFD animals. At last, (**E**) mRNA expression of Col1 and Ctgf-1 was assessed by qPCR. Student's *t* test with Welch's correction using GraphPad Prism software was used to determine significance. *\*P*\<0.05.](bsr-38-bsr20180721-g1){#F1}

Protein lysine acetylation is regulated by DIO in the LV {#sec3-2}
--------------------------------------------------------

Cardiac histone acetylation is a critical regulator of heart function, in which, changes in histone acetylation can contribute to cardiac hypertrophy and fibrosis, as well as loss of metabolic plasticity \[[@B5],[@B22]\]. More recently however, investigators have begun to emphasize the impact of non-histone acetylation in biology, this postulate was strengthened with findings that approximately 4500 proteins can be acetylated \[[@B7]\]. Indeed, recent developments have shown that sarcomeric proteins can be acetylated and that this is important for cardiac function \[[@B9],[@B10],[@B23],[@B24]\]. Given this, we first used standard SDS-PAGE and Western blot analysis to examine protein lysine acetylation. Animals on HFD had a significant increase in protein lysine acetylation in the LV compared with CD fed mice ([Figure 2](#F2){ref-type="fig"}A). Two different acetyl lysine antibodies, mouse monoclonal and rabbit polyclonal, were used to verify this phenomenon. Of note, no changes in lysine protein acetylation were observed in the gastrocnemius, white adipose tissue (epididymal), or liver ([Figure 2](#F2){ref-type="fig"}B--D, respectively), representing striated muscle and insulin-responsive tissues. These data suggest a cardiac tissue-specific phenomenon in animals exposed to 16 weeks of HFD.

![Obesity exacerbates cardiac tissue lysine acetylation\
Protein was isolated from (**A**) the LV, (**B**) gastrocnemius, (**C**) white epididymal adipose tissue, or (**D**) liver from mice fed a CD or HFD and immunoblotted for acetyl-lysine (α-rabbit), acetyl-lysine (α-mouse), acetyl-α-tubulin, total α-tubulin, and total H3.](bsr-38-bsr20180721-g2){#F2}

Obesity-mediated regulation of the cardiac proteome {#sec3-3}
---------------------------------------------------

Data presented above, demonstrate cardiac-specific regulation of lysine acetylation in response to DIO. As such, we next analyzed protein lysates from the LV of mice on a CD or HFD using LC MS analysis in order to identify and quantitate changes in total protein abundance and protein lysine acetylation. A workflow of the present study is summarized: (i) hearts were removed and LVs dissected from lean and obese mice in response to DIO, (ii) protein lysates were denatured, reduced, alkylated, and trypsin digested prior to TMT tagging, (iii) samples were then combined before sample fractionation and clean-up followed by (iv) MS/MS, (v) data were analyzed via Proteome Discoverer software, and (vi) bioinformatics analysis using IPA was performed ([Figure 3](#F3){ref-type="fig"}). TMT-tagged MS was chosen over stable isotope labeling with amino acids in cell culture (SILAC) for total protein and acetyl protein quantitation. TMT-tagged MS allows for multiplex analysis (up to ten samples per run), compared with SILAC (up to four samples per run). In addition, TMT-tagged MS does not require *in vivo* labeling, compared with food enrichment necessary for SILAC. As such, TMT-tagged MS has reduced proteomic costs and improved statistical power.

![Experimental proteomic workflow to examine the cardiac acetylome\
Representation of the experimental workflow to examine the cardiac acetylome. Hearts from obese animal were dissected and protein lysates TMT tagged and assessed via tandem MS prior to data analysis, interpretation, and IPA.](bsr-38-bsr20180721-g3){#F3}

TMT-tagged mass spectral analysis of four CD and five HFD mice LV protein samples identified a total of 4082 proteins. Abundance values obtained in all four CD and four out of five HFD cohorts met criteria for further study, which included 3928 of the 4082 identified proteins. Abundance values were normalized at the protein level, using the sum of the abundances of the pooled nine samples included on the multiplex. The average coefficient of variation (CV) across normalized protein abundances measured 25.3% for CD samples and 22.3% for HFD samples before quality control. A filtering step was used to reduce the overall CV in individual protein abundance values. Specifically, if exactly one outlier was 1.15 S.D. or more from the mean, it was removed. The maximum S.D. that is attainable in a sample with four replicates (CD cohort) is 1.5, and the maximum S.D. that is attainable in a sample with five replicates (HFD cohort) is 1.79; 15712 abundances were measured in the CD cohort and 20% of these were 1.15 S.D. or more from the mean protein abundance value. Similarly, 19640 abundances were measured in the HFD cohort and 14.4% of these were 1.15 S.D. or more from the mean protein abundance value and thus excluded. We found that these thresholds allow us to identify gross outlying individual data points within replicates and decrease the CV easily (only 17% of all data points were excluded) without excluding values of entire samples \[[@B25]\]. This simple quality control method identified grossly outlying replicates and decreased the average CV in the CD cohort to 14.8 and 15.3% in HFD cohort. Log~2~-transformed data followed a normal distribution.

Proteins were further filtered by only considering those with abundance levels for three out of four CD samples and three out of five HFD samples, and at least two peptides associated with the protein in each sample. This filtering protocol left 2515 proteins (Supplementary Table S1). Normalized data were first log~2~-transformed to follow a normal distribution. Simple Student's *t* tests were performed to assess differences in means of abundance levels between CD and HFD cohorts. A correction for the false discovery rate on the 2515 hypothesis tests was made \[[@B30]\]. Sixty-five of the 2515 proteins showed statistically significant differences with adjusted *P*-values of *P*\<0.1 (Supplementary Table S1). IPA determined these proteins to be involved in networks related to energy metabolism and production, cardiac necrosis and cardiovascular disease and endocrine function, with the top diseases related to metabolic disease and muscular disorders (Supplementary Table S2). In addition, IPA identified proteins from this screen that regulate cardiac enlargement, fibrosis, and heart failure.

Many of the proteins identified in the present study that showed increased expression with obesity are predominantly involved in energy utilization, either fatty acid β oxidation (e.g. malonyl-CoA decarboxylase (MLYCD)) or glucose oxidation (e.g. pyruvate dehydrogenase kinase isozyme 4 (PDK4)). For instance, IPA demonstrated both Kruppel-like factor 15 (KLF15) ([Figure 4](#F4){ref-type="fig"}A) and peroxisome proliferator-activated receptor α (PPARα) ([Figure 4](#F4){ref-type="fig"}B) to have a predicted activation based on downstream effectors showing increased protein expression. Proteins highlighted in red indicate increased protein expression and green indicate decreased protein expression impacted by obesity, where the predicted activated transcriptional regulators are highlighted in orange ([Figure 4](#F4){ref-type="fig"}A,B). KLF15 is a transcriptional regulator known to negatively regulate cardiac remodeling in response to stress \[[@B31]\], such as pressure overload \[[@B32]\]. PPARα is a nuclear transcription factor that when activated by a lipophilic ligand, such as free fatty acids, forms a heterodimer with the retinoid X receptor (RXR) \[[@B33]\]. The activated heterodimer complex translocates into the nucleus and binds to target genes involved in fatty acid uptake, fatty acid storage, and fatty acid β oxidation \[[@B14],[@B33]\].

![Obesity-mediated regulation of the cardiac proteome by KLF15 and PPARα transcriptional regulators\
(**A**,**B**) Pathway analysis (IPA) determined potential activation of the transcriptional regulators KLF15 and PPARα nuclear receptors by increased protein expression of downstream targets. Green highlighted proteins indicate a decrease in total protein expression and red indicate an increase in total protein expression. (**C**) IPA generated interaction map of KLF15 target proteins shown to be acetylated in this report. Green highlighted proteins indicate decreased acetylation and red indicate increased acetylation. Solid lines indicate direct protein--protein interactions, dashed lines indicate potential protein--protein interaction, and arrows imply directionality of protein--protein regulation.](bsr-38-bsr20180721-g4){#F4}

Obesity-mediated regulation of the cardiac acetylome {#sec3-4}
----------------------------------------------------

Similar to above, acetylated proteins were further filtered by considering those with abundance levels for three out of four CD samples and three out of five HFD samples, a minimum of two acetylated peptides associated with the protein in each sample were required for statistical analysis. This left 145 acetylated proteins (Supplementary Table S3). The same protein statistical analysis, performed above, was performed on the 145 acetylated proteins, 24 of the 145 acetylated proteins had *P*-values with *P*\<0.05 (Supplementary Table S3, highlighted in orange), and five acetylated proteins had adjusted *P*-values with *P*\<0.05 (Supplementary Table S3, highlighted in yellow). Principal Components (PCA) was performed on zero-centered, log~2~-transformed, normalized, and quality-controlled abundances on the 24 acetylated proteins using singular value decomposition, and showed a separation between high fat and control fat diets.

In addition to the above analyses, data of the four CD samples and five HFD samples were further extracted at the peptide level using Proteome Discoverer software. Using this software, 871 acetylated peptides were identified; 254 were unique peptides pertaining to a specific protein (Supplementary Table S4). The abundance of each acetylated peptide was normalized to the total abundance of its corresponding protein. This simple mathematical transformation provided a baseline of acetylated abundance for each peptide with respect to its protein. While enrichment is typical for examining protein modifications, our approach allowed for normalization of modified protein to its corresponding total protein with one simultaneous MS run. This limited our detection for low abundant acetylated proteins compared with standard enrichment. However, this approach of examining total protein lysate via TMT-tagged MS in combination with Proteome Discoverer software to determine peptide modification has the potential to limit technical biases associated with the combination of enrichment and MS analysis. This approach is additionally cost-effective as it limits multiple runs necessary for true acetyl/total protein normalization. Using this strategy, 189 unique acetylated proteins (Supplementary Table S5) were identified and the sum of the normalized abundances of the acetylated peptides associated with it was used for statistical testing across the CD and HFD cohorts. Specifically, simple Student's *t* tests were applied to the log~2~-transformed sum of normalized abundance data of the acetylated peptides for each protein, and any test with resulting *P*-value *P*\<0.1 was deemed statistically significant. This resulted in 14 acetylated proteins ([Table 1](#T1){ref-type="table"}) in which the acetylated peptide abundance showed a statistically significant difference between cohorts.

###### Obesity-mediated cardiac protein acetylation (acetylated peptides normalized to total protein)

  Protein                                                                                                           Accession   MW (kDa)   Modifications                                                                    Acetyl *P*-value
  ----------------------------------------------------------------------------------------------------------------- ----------- ---------- -------------------------------------------------------------------------------- ------------------
  Hemoglobin subunit β-1 OS = *Mus musculus* GN = Hbb-b1 PE = 1 SV = 2                                              P02088      15.8       Acetyl (K18; S50; S51; S53; K60; K62; T140)                                      0.003634997
  Hemoglobin subunit β-2 OS = *Mus musculus* GN = Hbb-b2 PE = 1 SV = 2                                              P02089      15.9       Acetyl (S53; K60; T140)                                                          0.010349192
  Polymerase I and transcript release factor OS = *Mus musculus* GN = Ptrf PE = 1 SV = 1                            O54724      43.9       Acetyl (T5)                                                                      0.030179358
  Peroxiredoxin-5: mitochondrial OS = *Mus musculus* GN = Prdx5 PE = 1 SV = 2                                       P99029      21.9       Acetyl (K70; K79)                                                                0.03226413
  Very long-chain specific acyl-CoA dehydrogenase: mitochondrial OS = *Mus musculus* GN = Acadvl PE = 1 SV = 3      P50544      70.8       Acetyl (K277; S306)                                                              0.036561309
  Dystonin OS = *Mus musculus* GN = Dst PE = 1 SV = 1                                                               S4R1P5      870.0      Acetyl (K4661)                                                                   0.038409617
  Aconitate hydratase: mitochondrial OS = *Mus musculus* GN = Aco2 PE = 1 SV = 1                                    Q99KI0      85.4       Acetyl (K144; K517; K523; K573)                                                  0.046165279
  Dihydrolipoyl dehydrogenase: mitochondrial OS = *Mus musculus* GN = Dld PE = 1 SV = 2                             O08749      54.2       Acetyl (K159; T165; K166; K410)                                                  0.058162495
  Titin OS = *Mus musculus* GN = Ttn PE = 1 SV = 1                                                                  E9Q8K5      3713.7     Acetyl (T11523; K20887)                                                          0.059301956
  DnaJ homolog subfamily B member 6 OS = *Mus musculus* GN = Dnajb6 PE = 1 SV = 1                                   G3X8S5      29.5       Acetyl (S112; K134)                                                              0.066036162
  Myosin regulatory light chain 2: ventricular/cardiac muscle isoform OS = *Mus musculus* GN = Myl2 PE = 1 SV = 3   P51667      18.9       Acetyl (S19)                                                                     0.071717402
  Actin: β skeletal muscle OS = *Mus musculus* GN = Acta1 PE = 1 SV = 1                                             P68134      42.0       Acetyl (K52; T150; T151; S273; T279; T280; S283; K317; T320; S325; T326; K328)   0.07295389
  ADP-ribosylation factor-like protein 1 OS = *Mus musculus* GN = Arl1 PE = 2 SV = 1                                P61211      20.4       Acetyl (S10; S11)                                                                0.092968836
  ATP synthase subunit O: mitochondrial OS = *Mus musculus* GN = Atp5o PE = 1 SV = 1                                Q9DB20      23.3       Acetyl (K162; K172)                                                              0.097114702

Abbreviation: Hbb-b1, hemoglobin subunit β-1.

From the 189 unique acetylated proteins identified (Supplementary Table S6), IPA demonstrated the top 15 canonical pathways significantly regulated by DIO ([Figure 6](#F6){ref-type="fig"}A). Statistical significance was determined by -log(*P*-value) and color coding was used to represent proteins in which acetylation was down-regulated, up-regulated, or not changed with the percentage of these lysine acetylated proteins impacted by DIO within each canonical pathway shown ([Figure 6](#F6){ref-type="fig"}A). Thus, while only 13.5% of the proteins in the mitochondrial dysfunction pathway were significantly impacted by obesity compared with the fatty acid β-oxidation pathway (\~25%), the lower *P*-value suggested greater probability of finding proteins in the mitochondrial dysfunction pathway to be altered ([Figure 6](#F6){ref-type="fig"}A). Indeed, of the 189 acetylated proteins, further stringent statistical parameters demonstrated that acetylation of 14 proteins were significantly regulated by DIO ([Table 1](#T1){ref-type="table"}), many of which are categorized in mitochondrial function (very long-chain specific Acyl-CoA dehydrogenase (ACADVL), aconitate hydratase 2 (ACO2), and dihydrolipoyl dehydrogenase (DLD)). From the 189 unique peptides identified (Supplementary Table S5) a *P*-value \>0.05 and log~2~ (0.6) threshold suggested that nine proteins were deacetylated and five proteins acetylated, respectively, and no change in acetylation for 175 proteins in response to DIO ([Figure 6](#F6){ref-type="fig"}B). Finally, using IPA, an overlapping canonical pathway map was generated ([Figure 6](#F6){ref-type="fig"}C). Gray boxes represent the canonical pathways in [Figure 6](#F6){ref-type="fig"}A, while black lines connecting the boxes reflect pathways that share at least ten acetylated proteins impacted by DIO ([Figure 6](#F6){ref-type="fig"}C).

With further examination, an overlay of acetylated proteins on the activated transcriptional regulators discussed above, KLF15 and PPARα, was performed. KLF15 is known to interact with nine of our identified acetylated proteins, including ACADVL ([Figure 4](#F4){ref-type="fig"}C and [Table 1](#T1){ref-type="table"}). Proteins highlighted in red indicate increased acetylation and green indicate decreased acetylation impacted by obesity. Color intensity reflects the log~2~ fold change, with darker shades of red, for example demonstrating a larger increase in protein acetylation in response to DIO. In addition, this pathway highlights protein--protein interactions, in which solid lines reflect expression interactions in response to obesity; arrows indicate directionality of regulation, and no arrow indicates inhibition. KLF15 is known to induce expression of all proteins shown with an exception to inhibiting MYOCD ([Figure 4](#F4){ref-type="fig"}C). PPARα is known to interact with 30 of our identified acetylated proteins, also including ACADVL, as well as α skeletal muscle actin (ACTA1) ([Figure 5](#F5){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Combined, these data suggest that protein acetylation has the potential to impact multiple pathways involved in cardiac cellular function in response to DIO.

![Obesity-mediated PPARα nuclear receptor regulation of the cardiac acetylome\
Pathway analysis (IPA) generated an interaction map of PPARα target proteins shown to be acetylated in this report. Green highlighted proteins indicate decreased acetylation and red indicate increased acetylation. Solid lines indicate direct protein--protein interactions, dashed lines indicate potential protein--protein interaction, and arrows imply directionality of protein--protein regulation.](bsr-38-bsr20180721-g5){#F5}

DIO impacts acetylation of proteins in the cardiovascular disease pathway {#sec3-5}
-------------------------------------------------------------------------

An IPA analysis report was performed, which outlines the top canonical pathways, diseases and functions by *P*-value on the proteins within our dataset to a related biological function. To summarize, the top five canonical pathways listed included Mitochondrial Dysfunction, Epithelial Adherens Junction Signaling, Oxidative Phosphorylation, TCA Cycle II (eukaryotic), and calcium signaling ([Figure 6](#F6){ref-type="fig"}A and Supplementary Table S5). Furthermore, the top five diseases and biological functions included Cardiovascular Disease, Organismal Injury and Abnormalities, Skeletal and Muscular Disorders, Developmental Disorder, and Hereditary Disorder (Supplementary Table S6). The top disease listed, Cardiovascular Disease, had a calculated *P*-value range of (1.43E^−16^, 4.58E^−04^) and included 47 of the 189 acetylated proteins previously identified. The Cardiovascular Disease Pathway consists of a specific set of functions; in which each has an individual calculated *P*-value contributing to the *P*-value range of the Cardiovascular Disease Pathway. The acetylated proteins associated with a related function within the Cardiovascular Disease Pathway are shown ([Figure 7](#F7){ref-type="fig"}). Proteins highlighted in red indicate increased acetylation and green indicate decreased acetylation impacted by obesity; proteins highlighted in white indicate no significant change. Color intensity reflects the log~2~ fold change, with darker shades of red indicating increased protein acetylation and bright green reflective of a greater decrease in protein acetylation in response to DIO ([Figure 7](#F7){ref-type="fig"}). In addition, this pathway highlights protein--protein interactions, in which solid lines reflect known interactions whereas dashed lines suggest potential interactions in response to obesity; arrows indicate directionality of protein--protein regulation. Based on this knowledge, we can observe that several proteins in the Cardiovascular Disease Pathway are significantly acetylated in response to DIO that includes ACO2 and DLD ([Figure 7](#F7){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Additionally, we report that these proteins can interact with regulators of nutrient sensing (e.g. 5′-AMP activated protein kinase (AMPK)). Thus, these data imply that non-histone protein acetylation is important for obesity-mediated cardiac pathology.

![Obesity-mediated regulation of the cardiac acetylome and pathway analysis\
IPA generated (**A**) stacked canonical pathways significantly affected by obesity, (**B**) comparison of down- and up-regulated acetylated proteins, and (**C**) the overlapping pathways in which ten or more acetylated proteins are shared.](bsr-38-bsr20180721-g6){#F6}

![Protein acetylation impacts proteins involved in the cardiovascular disease pathway\
Down-regulation and up-regulation of protein acetylation within the Cardiovascular Disease Pathway impacted by obesity. Green highlighted proteins indicate decreased acetylation, red indicate increased acetylation, and white indicate no significant changes in acetylation. Solid lines indicate direct protein--protein interactions, dashed lines indicate potential protein--protein interaction, and arrows imply directionality of protein--protein regulation.](bsr-38-bsr20180721-g7){#F7}

Discussion {#sec4}
==========

Unlike standard enrichment methods that allow for detection of low abundant peptide modifications, this report used TMT-tagged MS of total protein lysate to demonstrate a significant impact of obesity on total protein and non-histone protein acetylation in the LVs of mice. This method limited acetyl peptide yield typically obtained with enrichment, yet afforded us the opportunity to normalize protein acetylation to its corresponding total protein in the same run; this allowed proper examination of acetyl protein changes in response to DIO. We present strong statistical evidence that obesity-mediated protein acetylation impacted proteins involved in energy metabolism and sarcomere function. These findings are consistent with recent reports noting significant changes in protein acetylation, where acetylation sites were predominantly observed on mitochondrial, sarcomeric, or cytoskeletal proteins \[[@B15],[@B34],[@B35]\]. Combined, these findings highlight the potential impact for the cardiac acetylome as a critical regulator of cardiac pathophysiology, with our data emphasizing cardiometabolic re-programming of non-histone acetyl marks that may function to disrupt energy utilization and sarcomere activity.

Obesity contributes to the development of metabolic syndrome, in which increased energy intake exceeds energy expenditure. This results in an excess of mitochondrial oxidation products that propagates mitochondrial dysfunction and insulin resistance, contributing to an increased risk of cardiovascular disease \[[@B36]\]. Indeed, mice in this study had increased enlargement and fibrosis of the heart ([Figure 1](#F1){ref-type="fig"}). In addition, these animals were hyperglycemic and insulin resistant (data not shown). In response to metabolic dysfunction, we report that KLF15 and PPARα were predicted to have increased transcriptional activation, based on increased expression of downstream target genes ([Figure 4](#F4){ref-type="fig"}A,B). KLF15 and PPARα act as nodal regulators of energy metabolism, in which deletion of PPARα/KLF15 shifts fuel utilization from fatty acid oxidation toward glucose oxidation \[[@B11]\]. The observation that KLF15 phenocopies PPARα in the regulation of cardiac metabolism has been supported by Prosdocimo et al. \[[@B37]\], where KLF15 was shown to bind to PPARα in order to regulate a subset of genes necessary for cardiac lipid metabolism. Indeed, we report transcriptional overlap between KLF15 and PPARα in the regulation of proteins involved in glucose oxidation (PDK4) and lipid metabolism (MLYCD) in the heart ([Figure 4](#F4){ref-type="fig"}A,B, respectively). Increased PDK4 would be expected to attenuate glucose oxidation via inhibition of pyruvate dehydrogenase, while MLYCD would promote fatty acid oxidation via activation of carnitine palmitoyltransferase 1 (CPT1) \[[@B11],[@B38],[@B39]\]. Thus, these data would suggest disruption in metabolic homeostasis with increased nutrient demand; shifting toward fatty acid oxidation in place of glucose metabolism. This shift in metabolic homeostasis is common in states of metabolic dysfunction, where for instance in states of diabetes inhibition of insulin signaling shifts tissues toward fatty acid oxidation. Indeed, cardiac overexpression of PPARα mimics diabetic cardiomyopathy \[[@B40],[@B41]\]. Combined, these data would suggest that DIO activates KLF15/PPARα in a manner that promotes increased expression of proteins leading to metabolic dysfunction during pathological cardiac remodeling.

While downstream targets of KLF15 and PPARα were impacted at the level of total protein expression ([Figure 4](#F4){ref-type="fig"}A,B), proteins downstream of these nodal regulators also underwent PTMs that included acetylation/deacetylation ([Figures 4](#F4){ref-type="fig"}C and [5](#F5){ref-type="fig"}). One such protein, ACADVL had increased protein acetylation in animals exposed to HFD. KLF15 and PPARα were previously reported to regulate ACADVL expression in cardiac tissue \[[@B11],[@B33]\]. ACADVL catalyzes the first step in fatty acid β oxidation. Loss of ACADVL contributes to cardiomyopathy \[[@B42]\]. Interestingly, protein expression of ACADVL did not change in our DIO model, suggesting that acetylation may inhibit ACADVL activity and thus contribute to obesity-mediated metabolic dysfunction that contributes to cardiac remodeling and disease. Of note, ACADVL hyperacetylation was also reported in a transverse aortic constriction (TAC)-induced animal model of heart failure \[[@B34]\], further highlighting the potential role for ACADVL hyperacetylation in metabolic regulation. Studies have shown that sirtuin 3 (Sirt3), an NAD^+^-dependent HDAC, is important in cardiac disease, where loss of Sirt3 amplified cardiac remodeling \[[@B43]\]. This is of interest, as Sirt3 targets ACADVL for deacetylation \[[@B44]\]. Sirt3 expression is decreased with obesity \[[@B45]\]. These data would suggest that obesity-mediated down-regulation of Sirt3 potentially mediates ACADVL acetylation in the heart; whether KLF15/PPARα regulated Sirt3 in our model remains unknown. However, others have reported that Sirt3 co-localized with KLF15 in the nucleus of kidney cells \[[@B46]\]. Thus, KLF15/PPARα may interact with Sirt3 to regulate Sirt3 activity or expression in response to obesity and thus regulate ACADVL acetylation. These studies are currently underway.

Consistent with findings discussed above, we report that the Mitochondrial Dysfunction and TCA Cycle II (eukaryotic) pathways were two of the top three listed canonical pathways impacted by obesity ([Figure 6](#F6){ref-type="fig"}A and Supplementary Table S6), where protein acetylation was altered in 13.5% of proteins involved in the mitochondrial dysfunction pathway and 43.5% of proteins involved in TCA Cycle II pathway. ACO2, for instance plays an important role in the TCA cycle, where it interconverts citrate into its isomer isocitrate. We report a significant increase in ACO2 acetylation in response to obesity. Consistent with our data, a recent report demonstrated a significant increase in mitochondrial ACO2 acetylation in the heart of animals exposed to an HFD \[[@B47]\]. Using molecular modeling, these investigators further suggested that acetylation of K144 on ACO2 could perturb its tertiary structure and thus alter its enzymatic function \[[@B47]\]. However, as of yet, a direct physiological consequence for ACO2 acetylation in the heart has not been reported. Dehydrogenases also play an important role in mitochondrial function, where for instance, mutations of the *DLD* gene are associated with branched-chain ketoaciduria and Leigh disease \[[@B48]\]. While it was previously reported that DLD is acetylated in HeLa cells and mouse liver \[[@B48]\], we report for the first time that DLD acetylation increased in the hearts of obese mice. Similar to ACO2, the functional consequence of obesity-mediated DLD acetylation remains unknown. Combined, however, these data suggest that ACO2 and DLD acetylation regulates mitochondrial dysfunction in cardiac tissue; thus, obesity-induced acetylation of ACO2 and DLD potentially promotes cardiac pathology. The role of non-histone acetylation of proteins involved in energy metabolism require further investigation to determine how these modifications link obesity to cardiovascular disease.

Changes for mitochondrial protein hyperacetylation, as discussed above, were observed in our rodent model of DIO. The DIO model leads to severe obesity, glucose intolerance, hyperglycemia, and moderate insulin resistance. Moreover, this model can contribute to increased circulating triglycerides and free fatty acids \[[@B49]\]. As mentioned, elevated circulating free fatty acids contribute to increased cardiac β oxidation, providing an abundance of acetyl-CoA molecules for protein lysine acetylation \[[@B13],[@B14]\]. This would suggest that increased mitochondrial acetylation is unique to the obesity/diabetes phenotype. However, a recent report observed mitochondrial protein hyperacetylation in rodent models of heart failure and in end-stage failing human hearts \[[@B34]\], in which obesity and/or diabetes may be absent. Combined, this would suggest that mitochondrial protein hyperacetylation is an important regulator of metabolic dysfunction that has been linked to cardiac disease and is not dependent on metabolic phenotype. In that report \[[@B34]\], investigators performed mitochondrial fractionation studies from cardiac tissue to elucidate mitochondrial-specific protein targets. While our studies failed to use fractionated lysate, proteins identified in our analysis were shown in that report to locate to the mitochondria. Indeed, many of our acetylated proteins have been reported to localize to the mitochondria (e.g. ACO2) or the sarcomere (e.g. Titin), with additional proteins identified as circulating factors within the blood (i.e. hemoglobin). As the mitochondrial hyperacetylation report \[[@B34]\] did not examine sarcomeric proteins or circulating factors, it is possible that acetylation changes observed with these proteins are specific to the obesity/diabetes phenotype and therefore would imply that future studies examining protein acetylation in other compartments in response to cardiac stress are needed.

At last, comparisons between this report and previous investigations noted acetylation/deacetylation for many of the same proteins including ACO2, DLD, ACADVL, ACTA1, and LIM domain binding protein 3 (LDB3), with similarities and differences noted for sites of acetylation \[[@B7],[@B34]\]. For example, we report similar findings to Lundby et al. \[[@B7]\], in which DLD was acetylated on lysine residues 159 (K159) and 410 (K410) in the heart. Of interest, Lundby et al. \[[@B7]\] reported acetylation of hemoglobin subunit β-1 (Hbb-b1) in rat heart tissue at lysine residues 18 (K18) and 62 (K62). Similarly, we observed acetylation of Hbb-b1 at K18 and K62 in control mice, yet Hbb-b1 acetylation decreased in our DIO mice. In addition to Hbb-b1, we further observed deacetylation of hemoglobin subunit β-2 in the hearts of DIO mice. Findings that circulating proteins can be acetylated or deacetylated suggest that examination of acetyl-hemoglobin proteins or other acetylated circulating factors have the potential to serve as biomarkers for early cardiovascular disease detection. Indeed, many protein biomarkers serve for the evaluation and management of myocardial insults and cardiac remodeling; these include BNP, N-terminal proBNP, C-reactive protein, and Troponin T amongst others \[[@B50],[@B51]\]. In addition, hemoglobin content combined with serum folate levels have been suggested as potential biomarkers for Alzheimer's disease \[[@B52]\]. Combined, this would support further investigation into the role for acetylated or deacetylated circulating factors as biomarkers for cardiovascular disease; blood analysis from patients serves as a relatively simple and non-invasive procedure in the clinic.

In summary, our data highlight a potential role for non-histone protein acetylation in cardiac pathology. Further mechanistic investigation regarding the impact for protein acetylation on energy metabolism and sarcomeric function in response to physiological and pathological stress will yield novel insights in cardiac biology. Many of these mechanistic investigations are currently underway. At last, perturbations in acetylation are reversible, thus mechanistic insight regarding the cardiac acetylome may uncover novel therapeutic targets for the treatment of cardiometabolic disease.
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ACADVL

:   very long-chain specific Acyl-CoA dehydrogenase

ACO2

:   aconitate hydratase 2

ACTA1

:   α skeletal muscle actin

AGC

:   automatic gain control

ANP

:   atrial natriuretic peptide

BNP

:   brain natriuretic peptide

BPRP

:   basic pH reversed-phase

CD

:   control diet

Col1

:   collagen type 1

Ctgf-1

:   connective tissue growth factor 1

CV

:   coefficient of variation

DIO

:   diet-induced obesity

DLD

:   dihydrolipoyl dehydrogenase

Hbb-b1

:   hemoglobin subunit β-1

HDAC

:   histone deacetylase

HFD

:   high-fat diet

IPA

:   Ingenuity Pathway Analysis

KLF15

:   Kruppel-like factor 15

LV

:   left ventricle

MLYCD

:   malonyl-CoA decarboxylase

PDK4

:   pyruvate dehydrogenase kinase isozyme 4

PPARα

:   peroxisome proliferator-activated receptor α

PTM

:   post-translational modification

qPCR

:   quantitative PCR

qRT-PCR

:   quantitative real-time polymerase chain reaction

SILAC

:   stable isotope labeling with amino acids in cell culture

Sirt3

:   sirtuin 3

TMT

:   tandem mass tag
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